Determination of Regulatory Review Period for Purposes of Patent Extension; RECUVYRA; Affirmation
---
identifier: "/us/fr/2017-17961"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Determination of Regulatory Review Period for Purposes of Patent Extension; RECUVYRA; Affirmation"
title_number: 0
title_name: "Federal Register"
section_number: "2017-17961"
section_name: "Determination of Regulatory Review Period for Purposes of Patent Extension; RECUVYRA; Affirmation"
positive_law: false
currency: "2017-08-23"
last_updated: "2017-08-23"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2017-17961"
document_type: "notice"
publication_date: "2017-08-23"
agencies:
- "Health and Human Services Department"
- "Food and Drug Administration"
fr_citation: "82 FR 40008"
fr_volume: 82
docket_ids:
- "Docket Nos. FDA-2013-E-0264"
- "FDA-2013-E-0263"
- "and FDA-2013-E-0218"
fr_action: "Notification of affirmation."
---
# Determination of Regulatory Review Period for Purposes of Patent Extension; RECUVYRA; Affirmation
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Notification of affirmation.
**DATES:**
August 23, 2017
**FOR FURTHER INFORMATION CONTACT:**
Joyce Strong, Office of Policy, 10903 New Hampshire Ave., Bldg. 51, Silver Spring, MD 20993, 301-796-9148.
**SUPPLEMENTARY INFORMATION:**
The Food and Drug Administration (FDA) is affirming the signature date for a notice that appeared in the *Federal Register* on August 21, 2017 (82 FR 39587). The document announced FDA's determination for the regulatory review period for RECUVYRA. The document published with an incorrect date for the signature. We affirm that the document was signed on August 15, 2017.
Dated: August 21, 2017.
Leslie Kux,
Associate Commissioner for Policy.